hrp0084p3-963 | GH & IGF | ESPE2015

The Easypod™ Connect Observational Study: Comparison of Results from Interim Analyses

Davies Peter , Nicolino Marc , Norgren Svante , Stoyanov George , Koledova Ekaterina , VanderMeulen John

Background: The Easypod Connect Observational Study (ECOS) observational study follows children with GHD, SGA and Turner syndrome receiving r-hGH therapy for up to 5 years, with interim analyses each year. The easypod electromechanical auto-injector device enables accurate, real-world digital records of patientsÂ’ adherence to rhGH to be collected for evaluation.Objective and hypotheses: The primary objective of ECOS is to evaluate the level of adher...

hrp0086fc8.6 | Growth: Clinical | ESPE2016

Birth Characteristics Explain One Third of Expected Deaths in rhGH-treated Patients Diagnosed with IGHD, ISS & SGA

Albertsson-Wikland Kerstin , Martensson Anton , Savendahl Lars , Niklasson Aimon , Bang Peter , Dahlgren Jovanna , Gustafsson Jan , Kristrom Berit , Norgren Svante , Pehrsson Nils-Gunnar , Oden Anders

Background: That mortality is not increased in rhGH-treated patients when adjusting for birth characteristics was recently published (1). When applying a developed mortality model of the general population, the observed and expected deaths in rhGH-treated IGHD, ISS and SGA patients (n=3847) where 21 and 21.99, respectively. The model includes gender, age, calendar year, gestational age (GA), birth lengthSDS (BLSDS), birth weightSDS (BW...